Anterogen.Co.,Ltd.
Financials
Valuation Metrics
Anterogen.Co.,Ltd.'s Market Cap is ₩1353B. At end of 2025 it was ₩4688B. Ranked #1025 of 2,405 in KR market (top 43%), #519 of 1,627 on KOSDAQ (top 32%), #122 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 135.28B KRW | KR#1,025/2,405 Sec#122/231 |
| Revenue | 8.37B KRW | KR#2,289/2,405 Sec#181/231 |
| Net Income | -1.62B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 88.26B KRW | KR#1,874/2,405 Sec#152/231 |
| Net Assets | 87.45B KRW | KR#1,509/2,405 Sec#119/231 |
| Employees | 29 | KR#2,195/2,405 Sec#206/231 |
| Value | ||
| P/B | 1.55x | KR#1,830/2,405 Sec#131/231 |
| P/S | 16.16x | KR#2,315/2,405 Sec#181/231 |
| FCF Yield | -0.83% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -1.85% | KR#1,676/2,405 Sec#117/231 |
| ROA | -1.83% | KR#1,735/2,405 Sec#123/231 |
| Op. Margin | -29.40% | KR#2,162/2,405 Sec#154/231 |
| Revenue Growth | 16.55% | KR#632/2,405 Sec#59/231 |
| Financial Health | ||
| Debt Ratio | 0.93% | KR#3/2,405 Sec#2/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | -1.12B KRW | KR#1,283/2,405 Sec#98/231 |
| Cash | 1.58B KRW | KR#2,275/2,405 Sec#216/231 |
| Performance | ||
| 1Y Return | -40.04% | KR#1,702/2,405 Sec#139/231 |
| 1M Return | -10.11% | KR#1,178/2,405 Sec#113/231 |
| From 52W High | -78.12% | KR#2,260/2,405 Sec#205/231 |
| 1Y MDD | -76.97% | KR#2,203/2,405 Sec#193/231 |
| Trading | ||
| Volume | 16,882 shares | KR#1,592/2,405 Sec#157/231 |
| Trading Value | 223.3M KRW | KR#1,086/2,405 Sec#120/231 |
| Foreign Own. | 4.25% | KR#990/2,405 Sec#89/231 |
| Per Share | ||
| EPS | -162 KRW | KR—/2,405 Sec—/231 |
| BPS | 8,739 KRW | KR#1,085/2,405 Sec#75/231 |
Company Info
Antrogen, established in 2000 and listed on KOSDAQ in 2016, is a specialized stem cell therapy bio-venture. In 2012, it gained the world's first marketing approval for Cupistem, an adipose-derived stem cell product for Crohn's fistula, and holds exclusive domestic sales rights for pulmonary hypertension treatments Remodulin and Tyvaso. Through its diverse disease pipeline, Antrogen is expanding its business and strengthening its competitive edge in rare and intractable disease treatments. It is headquartered in Geumcheon-gu, Seoul.